A phase 1/2 trial of SMP3124LP in advanced solid tumours, run by Sumitomo Pharma America, Inc., now recruiting.
SMP-3124LP in Adults With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06526819 by Sumitomo Pharma America, Inc., with 120 participants planned, started 2024-08-14 and due to reach its primary completion in 2028-12. Interventions recorded: SMP3124LP.
Shares Sumitomo Pharma (Myovant) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.